Stryker Corporation $SYK Shares Sold by Magellan Asset Management Ltd

Posted by Brenda Bartman on Jul 22nd, 2026

Magellan Asset Management Ltd decreased its holdings in Stryker Corporation (NYSE:SYK – Free Report) by 11.0% in the 1st quarter, Holdings Channel reports. The firm owned 301,120 shares of the medical technology company’s stock after selling 37,185 shares during the period. Magellan Asset Management Ltd’s holdings in Stryker were worth $98,945,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of SYK. Sankala Group LLC purchased a new position in shares of Stryker during the fourth quarter worth about $26,000. United Financial Planning Group LLC purchased a new stake in shares of Stryker during the third quarter worth approximately $27,000. Godfrey Financial Associates Inc. acquired a new stake in shares of Stryker during the fourth quarter worth $26,000. Atlas Capital Advisors Inc. acquired a new position in Stryker in the 4th quarter valued at $27,000. Finally, Strive Asset Management LLC acquired a new stake in shares of Stryker in the 3rd quarter worth $30,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Price Performance

Stryker stock opened at $313.89 on Wednesday. The firm has a market capitalization of $120.33 billion, a PE ratio of 36.33, a P/E/G ratio of 2.04 and a beta of 0.77. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.87. The firm’s 50-day simple moving average is $313.79 and its 200 day simple moving average is $336.20. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK – Get Free Report) last posted its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. During the same quarter last year, the business posted $2.84 earnings per share. The business’s revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities research analysts predict that Stryker Corporation will post 14.99 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio is 40.74%.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. BMO Capital Markets initiated coverage on shares of Stryker in a report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 price target for the company. Sanford C. Bernstein set a $410.00 price target on Stryker in a research note on Friday, May 1st. Robert W. Baird set a $385.00 price objective on Stryker in a research report on Friday, May 1st. Evercore set a $350.00 price target on shares of Stryker in a research note on Monday, July 6th. Finally, BTIG Research set a $371.00 price objective on shares of Stryker in a research note on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $392.52.

View Our Latest Report on SYK

Insiders Place Their Bets

In related news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the transaction, the vice president directly owned 13,137 shares of the company’s stock, valued at $3,728,937.45. The trade was a 28.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 323,264 shares of company stock valued at $100,659,489. Corporate insiders own 4.60% of the company’s stock.

Stryker Profile

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.